DOCSLIB.ORG

(NCCN Guidelines®) Hodgkin Lymphoma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(NCCN Guidelines®) Hodgkin Lymphoma NCCN Guidelines Index Hodgkin Table of Contents Discussion NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines® ) Hodgkin Lymphoma Version 2.2013 NCCN.org Continue Version 2.2013, 05/24/13 © National Comprehensive Cancer Network, Inc. 2013, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN® . NCCN Guidelines Version 2.2013 Panel Members NCCN Guidelines Index Hodgkin Table of Contents Hodgkin Lymphoma Discussion * Richard T. Hoppe, MD/Chair § Robert Chen, MD ‡ x Monika Metzger, MD € Stanford Cancer Institute City of Hope Comprehensive Cancer Center St. Jude Children’s Research Hospital/ University of Tennessee Health Science Ranjana Hira Advani, MD † Bouthaina Dabaja, MD § Center Stanford Cancer Institute The University of Texas M. D. Anderson Cancer Center Joseph O. Moore, MD † Weiyun Z. Ai, MD ‡ Duke Cancer Institute UCSF Helen Diller Family Andres Forero, MD † ‡ Comprehensive Cancer Center University of Alabama at Birmingham David Morgan, MD †‡x Comprehensive Cancer Center Vanderbilt-Ingram Cancer Center Richard F. Ambinder, PhD, MD † The Sidney Kimmel Comprehensive Leo I. Gordon, MD ‡ Craig H. Moskowitz, MD † Þ Cancer Center at John Hopkins Robert H. Lurie Comprehensive Cancer Memorial Sloan-Kettering Cancer Center Center of Northwestern University Patricia Aoun, MD, MPH ¹ Matthew Poppe, MD § City of Hope Comprehensive Francisco J. Hernandez-Ilizaliturri, MD † Huntsman Cancer Institute Cancer Center Roswell Park Cancer Institute at the University of Utah Celeste M. Bello, MD, MSPH † Ephraim P. Hochberg, MD † Barbara Pro, MD † Þ Moffitt Cancer Center Massachusetts General Hospital Cancer Center Fox Chase Cancer Center Cecil M. Benitez, BS ¥ David G. Maloney, MD, PhD †‡ Jane N. Winter, MD ‡ Stanford Cancer Institute Fred Hutchinson Cancer Research Robert H. Lurie Comprehensive Cancer Center/Seattle Cancer Care Alliance Center of Northwestern University Philip J. Bierman, MD † ‡ x UNMC Eppley Cancer Center at David Mansur, MD § Joachim Yahalom, MD § The Nebraska Medical Center Siteman Cancer Center at Barnes- Memorial Sloan-Kettering Cancer Center Jewish Hospital and Washington Kristie A. Blum, MD ‡ University School of Medicine NCCN The Ohio State University Kristina Gregory, RN, MSN, OCN Comprehensive Cancer Center - Peter M. Mauch, MD § Hema Sundar, PhD James Cancer Hospital and Dana-Farber/Brigham and Women's Solove Research Institute Cancer Center § Radiation oncology † Medical oncology ‡ Hematology/Hematology oncology Continue x Bone marrow transplantation € Pediatric oncology ¹ Pathology Þ Internal medicine NCCN Guidelines Panel Disclosures ¥ Patient advocacy Version 2.2013, 05/24/13 © National Comprehensive Cancer Network, Inc. 2013, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN® . NCCN Guidelines Version 2.2013 Table of Contents NCCN Guidelines Index Hodgkin Table of Contents Hodgkin Lymphoma Discussion NCCN Hodgkin Lymphoma Panel Members Clinical Trials: NCCN believes that Summary of Guidelines Updates the best management for any cancer Diagnosis and Workup (HODG-1) patient is in a clinical trial. Participation in clinical trials is Primary Treatment especially encouraged. · Classical Hodgkin Lymphoma: To find clinical trials online at NCCN CS IA-IIA Favorable (HODG-2) Member Institutions, click here: CS I-II Unfavorable (Bulky disease) (HODG-4) nccn.org/clinical_trials/physician.html. CS I-II Unfavorable (Non-bulky disease) (HODG-9) NCCN Categories of Evidence and CS III-IV (HODG-11) Consensus: All recommendations are category 2A unless otherwise · Lymphocyte-Predominant Hodgkin Lymphoma: specified. CS I-IV (HODG-14) See NCCN Categories of Evidence Follow-up After Completion of Treatment and Consensus. and Monitoring For Late Effects (HODG-15) Refractory Classical Hodgkin Lymphoma (HODG-16) Suspected Relapse of Classical Hodgkin Lymphoma (HODG-17) Refractory or Relapsed Lymphocyte-Predominant Hodgkin Lymphoma (HODG-18) Unfavorable Factors (localized and advanced disease) (HODG-A) Principles of Systemic Therapy (HODG-B) Principles of Radiation Therapy (HODG-C) Deauville PET Criteria (HODG-D) Principles of Second-line Chemotherapy (HODG-E) Staging (ST-1) The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer Network®® (NCCN ) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network® . All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2013. Version 2.2013, 05/24/13 © National Comprehensive Cancer Network, Inc. 2013, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN® . NCCN Guidelines Version 2.2013 Updates NCCN Guidelines Index Hodgkin Table of Contents Hodgkin Lymphoma Discussion Summary of the changes in the 2.2013 version of the NCCN Guidelines for Hodgkin Lymphoma from the 1.2013 version include: MS-1 - The discussion section was updated to reflect the changes in the algorithm. Summary of the changes in the 1.2013 version of the NCCN Guidelines for Hodgkin Lymphoma from the 2.2012 version include: HODG-1 HODG-2 Diagnosis · Footnote “h” modified:Excludes the NCCN Unfavorable Factors for · Immunohistochemistry evaluation highly recommended for stage I-II disease: bulky mediastinal or >10 cm disease, B symptoms, Hodgkin lymphoma. ESR >50, >3 sites of disease (see Unfavorable Factors HODG-A). · Footnote “b” modified: “Typical immunophenotype for Classical · Previous footnote “m” deleted: “Patients with elevated ESR or >3 sites Hodgkin lymphoma: CD15+, CD30+,PAX-5+ (weak) ; CD3-, CD20 - of disease may be managed with Stanford V per this algorithm.” · (majority), CD45-, CD79a-. Typical immunophenotype for Footnote “o” added with link to Deauville PET criteria. · Footnote “r” modified: Biopsy to confirm no change in histology. Lymphocyte-predominant Hodgkin lymphoma: CD20+, CD45+, Clinical circumstances may warrant additional treatment even in face CD79a+, BCL6+, PAX-5+; CD3-, CD15-, CD30-. An expanded panel of negative biopsy. (also applies to HODG-3 through HODG-13, HODG- of markers may be required especially if equivocal diagnosis. See 16) NHL Guidelines. · Footnote “s” added: “Deauville 3 should have short interval follow-up Workup including PET-CT.” (also applies to HODG-3, HODG-10, HODG-13 · HIV test moved from “Essential” to “Useful in selected cases” and HODG-16 through HODG-18) “encouraged” added. · HODG-3 Neck CT: “if neck RT contemplated” added. · Restaging modified: Restage after chemotherapy with PET-CT CT · “Fertility preservation” added to “Useful in selected cases” with through regions of initial disease footnote “e”: “Fertility preservation options include: · Deauville criteria added to determine further treatment options. Semen cryopreservation, if chemotherapy or pelvic RT · Footnote “o” added with link to Deauville PET criteria. contemplated. IVF or ovarian tissue or oocyte cryopreservation. · Pathway for stable disease removed. Oophoropexy in pre-menopausal women if pelvic RT is HODG-4 contemplated.” · Primary treatment: ABVD changed from 4 cycles to “2-4 cycles” and HODG-2 listed as a category 1 recommendation. Primary treatment · Primary treatment: BEACOPP x 2 + ABVD x 2 + RT added as a · Combined modality therapy (ABVD x 2-4 cycles + involved-site RT treatment option. (ISRT) (category 1) or Stanford V x 8 weeks) + involved field RT · Deauville criteria added to determine further treatment options. [IFRT]) (category 1) · Footnote “o” added with link to Deauville PET criteria. · ABVD alone changed from a category 2B recommendation to a · Deauville 1-3 after restaging: ABVD changed from 2 cycles to “2-4 category 2A recommendation. cycles” and IFRT removed as a treatment option. · Restaging modified: Restage after chemotherapy with PET-CT CT · Deauville 4 after restaging: ABVD changed from 2 cycles to “2-4 through regions of initial disease. · Deauville criteria added to determine further treatment options. cycles.” · Deauville 1-3: recommendation after ISRT changed to “Observe.” · Deauville 4: Restaging after 4-6 cycles of ABVD moved to · Deauville 4: Biopsy added as an option. page HODG-5. Version 2.2013, 05/24/13 © National Comprehensive Cancer Network, Inc. 2013, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN® . UPDATES NCCN Guidelines Version 2.2013 Updates NCCN Guidelines Index Hodgkin Table of Contents Hodgkin Lymphoma Discussion Summary of the changes in the 1.2013 version of the NCCN Guidelines for Hodgkin Lymphoma from the 2.2012 version include: HODG-5 HODG-11 · Deauville criteria added to determine further treatment options. · Previous footnote “y” deleted: “If stable disease after 2 cycles of · Footnote “o” added with link to Deauville PET criteria. ABVD, consider a total of
Load more

Recommended publications
  • Hodgkin Lymphoma Treatment Regimens
    HODGKIN LYMPHOMA TREATMENT REGIMENS (Part 1 of 5) Clinical Trials: The National Comprehensive Cancer Network recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced health care team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are provided only to supplement the latest treatment strategies. These Guidelines are a work in progress that may be refined as often as new significant data become available. The NCCN Guidelines® are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. Classical Hodgkin Lymphoma1 Note: All recommendations are Category 2A unless otherwise indicated. Primary Treatment Stage IA, IIA Favorable (No Bulky Disease, <3 Sites of Disease, ESR <50, and No E-lesions) REGIMEN DOSING Doxorubicin + Bleomycin + Days 1 and 15: Doxorubicin 25mg/m2 IV push + bleomycin 10units/m2 IV push + Vinblastine + Dacarbazine vinblastine 6mg/m2 IV over 5–10 minutes + dacarbazine 375mg/m2 IV over (ABVD) (Category 1)2-5 60 minutes.
    [Show full text]
  • Vincristine (Conventional): Drug Information
    Official reprint from UpToDate® www.uptodate.com ©2017 UpToDate® Vincristine (conventional): Drug information Copyright 1978-2017 Lexicomp, Inc. All rights reserved. (For additional information see "Vincristine (conventional): Patient drug information" and see "Vincristine (conventional): Pediatric drug information") For abbreviations and symbols that may be used in Lexicomp (show table) Special Alerts Vincristine Sulfate Safety Alert October 2015 Health Canada is notifying health care providers that certain lots of Hospira’s vincristine sulfate 1 mg/mL injection (DIN 02183013: 2 mL vial, list #7077A001; 5 mL vial, list #7082A001) have incorrect or outdated safety information on the inner/outer labels and package insert, which may increase the risk to patients and may result in significant patient harm requiring medical intervention. These warnings include: - Vincristine should only be administered by the intravenous (IV) route. Administration of vincristine by any other route can be fatal. - Syringes containing this product should be labeled “Warning - for IV use only.” - Extemporaneously prepared syringes containing this product must be packaged in an overwrap which is labeled “Do not remove covering until moment of injection. For IV use only - fatal if given by other routes.” - Contraindication of vincristine in patients with demyelinating Charcot-Marie-Tooth syndrome. - Potential risk of acute shortness of breath when vincristine is coadministered with mitomycin-C and GI toxicities including necrosis with administration of vincristine. Health care providers are requested to consult with the approved Canadian product monograph for vincristine sulfate 1 mg/mL for the most updated information. Consumers with questions should contact their health care provider for more information. ALERT: US Boxed Warning Experienced physician: Vincristine should be administered by individuals experienced in the administration of the drug.
    [Show full text]
  • HODGKIN LYMPHOMA TREATMENT REGIMENS (Part 1 of 2)
    HODGKIN LYMPHOMA TREATMENT REGIMENS (Part 1 of 2) The selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. Drug dose modifications and schedule and initiation of supportive care interventions are often necessary because of expected toxicities and because of individual patient variability, prior treatment, and comorbidities. Thus, the optimal delivery of anticancer agents requires a healthcare delivery team experienced in the use of such agents and the management of associated toxicities in patients with cancer. The cancer treatment regimens below may include both FDA-approved and unapproved uses/regimens and are provided as references only to the latest treatment strategies. Clinicians must choose and verify treatment options based on the individual patient. NOTE: GREY SHADED BOXES CONTAIN UPDATED REGIMENS. REGIMEN DOSING Classical Hodgkin Lymphoma—First-Line Treatment General treatment note: Routine use of growth factors is not recommended. Leukopenia is not a factor for treatment delay or dose reduction (except for escalated BEACOPP).1 CR=complete response IPS=International Prognostic Score PD=progressive disease PFTs=pulmonary function tests PR=partial response RT=radiation therapy SD=stable disease Stage IA, IIA Favorable ABVD (doxorubicin [Adriamycin] Days 1 and 15: Doxorubicin 25mg/m2 IV + bleomycin 10mg/m2 IV + vinblastine + bleomycin + vinblastine + 6mg/m2 IV + dacarbazine 375mg/m2 IV. dacarbazine [DTIC-Dome]) + Repeat cycle every 4 weeks for 2–4 cycles. involved-field radiotherapy (IFRT)1–4 Follow with IFRT after completion of chemotherapy. Abbreviated Stanford V Weeks 1, 3, 5 and 7: Vinblastine 6mg/m2 IV + doxorubicin 25mg/m2 IV. (doxorubicin + vinblastine + Weeks 1 and 5: Mechlorethamine 6mg/m2.
    [Show full text]
  • Hodgkin Lymphoma
    Hodgkin Lymphoma Erica, Hodgkin lymphoma survivor Revised 2016 Publication Update Hodgkin Lymphoma The Leukemia & Lymphoma Society wants you to have the most up-to-date information about blood cancer treatment. See below for important new information that was not available at the time this publication was printed. In May 2017, the Food and Drug Administration (FDA) approved nivolumab (Opdivo®) for the treatment of adult patients with classical Hodgkin lymphoma (HL) that has relapsed or progressed after 3 or more lines of systemic therapy that includes autologous hematopoietic stem cell transplantation (HSCT). It is also approved for the treatment of adult patients with classical HL that has relapsed or progressed after autologous HSCT and brentuximab vedotin. These indications are approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. In March 2017, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda®) for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or who have relapsed after 3 or more prior lines of therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. For more information, contact an Information Specialist at (800) 955-4572 or [email protected]. Information Specialists: 800.955.4572 I www.LLS.org PS57 A Message from Louis J. DeGennaro, PhD President and CEO of The Leukemia & Lymphoma Society The Leukemia & Lymphoma Society (LLS) is the world’s largest voluntary health organization dedicated to finding cures for blood cancer patients.
    [Show full text]
  • Highlights from the Pan Pacific Lymphoma Conference
    October 2011 A SPECIAL MEETING REVIEW EDITION Volume 9, Issue 10, Supplement 24 Highlights From the Pan Pacific Lymphoma Conference August 15–19, 2011 Kauai, Hawaii Special Reporting on: • Aggressive T-Cell Lymphomas • Novel Agents With Activity in CLL/SLL • PTCL—Update on Novel Therapies • Agents Targeting the Stromal Elements of the Lymph Node • Inducing Apoptosis in Lymphoma Cells Through Novel Agents With Expert Commentary by: Bruce D. Cheson, MD Deputy Chief Division of Hematology-Oncology Head of Hematology Lombardi Comprehensive Cancer Center Georgetown University Hospital Washington, DC Eb: E W Th O N www.clinicaladvances.com ENGINEERING T H E N E X T GENERATION OF ANTIBODY-DRUG CONJUGATES 003203_sgncor_adcadvcaho_fa4.indd 2 8/25/11 11:13 AM An innovative approach to improving outcomes in patients with cancer Antibody-drug conjugates (ADCs) use a conditionally stable linker to combine the targeting specificity of monoclonal antibodies with the tumor-killing power of potent cytotoxic agents.1,2 This could allow potent drugs to be delivered directly to tumor cells with minimal systemic toxicity. Optimizing the parameters for clinical success Scientists at Seattle Genetics are focused on parameters critical to the effective performance of ADCs, including target antigen selection,3,4 linker stability5-7 and potent cytotoxic agents.4,7,8 Elements of an antibody-drug conjugate Linker ADCs link precision and Antibody attaches the cytotoxic agent to specific for a tumor-associated the antibody. Newer linker potency for greater activity
    [Show full text]
  • Older Patients
    Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study by Andrew M. Evens, Joseph M. Connors, Anas Younes, Stephen M. Ansell, Won Seog Kim, John Radford, Tatyana Feldman, Joseph Tuscano, Kerry J. Savage, Yasuhiro Oki, Andrew Grigg, Christopher Pocock, Monika Dlugosz-Danecka, Keenan Fenton, Andres Forero-Torres, Rachael Liu, Hina Jolin, Ashish Gautam, and Andrea Gallamini Haematologica 2021 [Epub ahead of print] Citation: Andrew M. Evens, Joseph M. Connors, Anas Younes, Stephen M. Ansell, Won Seog Kim, John Radford, Tatyana Feldman, Joseph Tuscano, Kerry J. Savage, Yasuhiro Oki, Andrew Grigg, Christopher Pocock, Monika Dlugosz-Danecka, Keenan Fenton, Andres Forero-Torres, Rachael Liu, Hina Jolin, Ashish Gautam, and Andrea Gallamini. Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study. Haematologica. 2021; 106:xxx doi:10.3324/haematol.2021.278438 Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in print on a regular issue of the journal. All legal disclaimers that apply to the journal also pertain to this production process.
    [Show full text]
  • Frontline Paid New York, Ny a Lymphoma Rounds Publication Permit #370
    Lymphoma Rounds Leadership Chicago - Loyola University Chicago New England - Baystate Medical MD, PhD; Francesca Montanari, Anna Niewiarowska, MD - Scott Smith, MD, PhD, FACP; Center - Armen Asik, MD; Beth MD; Hackensack University Medical Patrick Stiff, MD; Northwestern Israel Deaconess Medical Center Center - Andre Goy, MD, MS; Icahn Seattle - Kaiser Permanente University - Leo Gordon, MD, - Jon Arnason, MD; Robin Joyce, School of Medicine at Mount Sinai - Washington - Eric Chen, MD, PhD; FACP; Reem Karmali, MD, MS MD; Boston University School of Joshua Brody, MD; Memorial Sloan The Polyclinic - Sherry Hu, MD, (chair); Jane Winter, MD; Rush Medicine - J. Mark Sloan, MD; Kettering Cancer Center - Anthony PhD; Swedish Medical Center - University Medical Center - Jerome Brown University School of Medicine Mato, MD, MSCE; David Straus, Hank Kaplan, MD; John Pagel, Loew, MD; Sunita Nathan, MD; - Adam Olszewski, MD; Dana- MD (chair); NYU Langone Medical MD, PhD, DSc (chair); University of Parameswaran Venugopal, MD; Farber Cancer Institute - Jorge Center - Catherine Diefenbach, Washington - Paul S. Martin, MD; The University of Chicago - Sonali Castillo, MD; Ann LaCasce, MD, MD; Rutgers Cancer Institute of The University of Washington/Fred Smith, MD; Girish Venkataraman, MSc; Dartmouth-Hitchcock Medical New Jersey - Joseph Bertino, MD; Hutchinson Cancer Research Center MD; University of Illinois at Chicago Center - Elizabeth Bengtson, Andrew Evens, DO, MSc, FACP; - Stephen Smith, MD; Virginia - Frederick Behm, MD; David MD; Erick Lansigan, MD; Lahey Weill Cornell Medicine - Koen van Mason Medical Center - David Peace, MD Hospital and Medical Center - Tarun Besien, MD, PhD; Ethel Cesarman, Aboulafia, MD Kewalramani, MD; Massachusetts MD, PhD; Amy Chadburn, MD; Los Angeles - Cedars-Sinai Medical General Hospital Cancer Center- Morton Coleman, MD Washington, D.C.
    [Show full text]
  • Adcetris, INN-Brentuximab Vedotin
    19 July 2012 EMA/702390/2012 Committee for Medicinal Products for Human Use (CHMP) Assessment report Adcetris International non-proprietary name: brentuximab vedotin Procedure No. EMEA/H/C/002455 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E -mail [email protected] Website www.ema.europa.eu An agency of the European Union Product information Name of the medicinal product: Adcetris Applicant: Takeda Global Research and Development Centre (Europe) Ltd. 61 Aldwych London WC2B 4AE United Kingdom Active substance: brentuximab vedotin International Nonproprietary Name/Common Name: brentuximab vedotin Pharmaco-therapeutic group Monoclonal antibodies (ATC Code): (L01XC12) ADCETRIS is indicated for the treatment of adult Therapeutic indication(s): patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): 1. following autologous stem cell transplant (ASCT) or 2. following at least two prior therapies when ASCT or multi-agent chemotherpay are not a treatment option ADCETRIS is indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). Pharmaceutical form(s): Powder for concentrate for solution for infusion Strength(s): 50 mg Route(s) of administration: Intravenous use Packaging: vial (glass) Package size(s): 1 vial Adcetris CHMP assessment report Page 2/102 Rev10.11 Table of contents 1. Background information on the procedure .............................................. 9 1.1. Submission of the dossier ...................................................................................... 9 1.2. Steps taken for the assessment of the product ....................................................... 10 2. Scientific discussion .............................................................................
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,545.449 B2 Krantz (45) Date of Patent: Jan
    USOO9545449B2 (12) United States Patent (10) Patent No.: US 9,545.449 B2 Krantz (45) Date of Patent: Jan. 17, 2017 (54) SITE-SPECIFIC LABELING AND TARGETED 8,030.459 B2 10/2011 Papisov et al. DELIVERY OF PROTEINS FOR THE 8,927.485 B2 1/2015 Krantz et al. 2003/0215877 A1 11/2003 Love et al. TREATMENT OF CANCER 2005, 00792O8 A1 4/2005 Albani 2007, 0123465 A1 5/2007 Adermann et al. (71) Applicant: Advanced Proteome Therapeutics 2010.0099649 A1* 4/2010 Krantz et al. ................. 514f131 Inc., Boston, MA (US) 2011 0002978 A1 1/2011 Harrison 2011/0263832 A1 10/2011 Krantz et al. (72) Inventor: Alexander Krantz, Boston, MA (US) 2013,0165382 A1 6/2013 Krantz et al. (73) Assignee: Advanced Proteone Therapeutics Inc., FOREIGN PATENT DOCUMENTS Boston, MA (US) WO WO-89/11867 A1 12/1989 WO WO-02/42427 A2 5, 2002 (*) Notice: Subject to any disclaimer, the term of this WO WO-O2/O87497 A2 11/2002 patent is extended or adjusted under 35 WO WO-03/093478 A1 11, 2003 U.S.C. 154(b) by 0 days. WO WO-2007 112362 A2 10, 2007 WO WO-2010, 140886 A1 12/2010 (21) Appl. No.: 14/400,190 WO WO-2011, 153250 A2 12/2011 (22) PCT Filed: May 13, 2013 OTHER PUBLICATIONS (86). PCT No.: PCT/US2O13/040823 Yu et al. Site-specific crosslinking of annexin proteins by 1.4- benzoquinone: a novel crosslinker for the formation of protein S 371 (c)(1), dimers and diverse protein conjugates (Org. Biomol. Chem..., 2012, (2) Date: Nov.
    [Show full text]
  • Brentuximab Vedotin: First-Line Agent for Advanced Hodgkin Lymphoma
    ANTICANCER RESEARCH 33: 3879-3886 (2013) Brentuximab Vedotin: First-line Agent for Advanced Hodgkin Lymphoma HUYNH CAO1, KENNETH YAMAMOTO1, LI-XI YANG1,2 and ROBERT WEBER1 1St. Mary’s Medical Center, San Francisco, CA, U.S.A.; 2Radiobiology Laboratory, California Pacific Medical Center Research Institute, San Francisco, CA, U.S.A. Abstract. Hodgkin lymphoma (HL) is characterized by The mortality rate of Hodgkin lymphoma (HL) has fallen malignant Reed-Sternberg cells which express CD30. rapidly in the United States in the past five decades due to Current National Comprehensive Cancer Network guidelines the development of multiagent therapies. Among adults, for patients with advanced HL (stage III/IV disease) there are about 9,060 new cases with a reported death of recommend adriamycin, bleomycin, vinblastine, and 1,190 in 2012 (1). Current standard first-line regimens dacarbazine (ABVD), or escalated bleomycin, etoposide, include adriamycin, bleomycin, vinblastine, dacarbazine adriamycin, cyclophosphamide, vincristine, procarbazine, (ABVD), bleomycin, etoposide, adriamycin, cyclo- and prednisone (BEACOPP) as first-line regimens. ABVD phosphamide, vincristine, procarbazine, prednisone appears to be as effective, with fewer side effects, as (BEACOPP) and Stanford V. Brentuximab vedotin, the first escalated BEACOPP. Escalated BEACOPP leads to a Food and Drug Administration (FDA)-approved agent for the greater progression-free survival but no difference in overall treatment of HL in over three decades, has been well-studied survival. Recent advancements in technology have enabled in many trials as a second-line agent after prior failed an exciting shift to molecular-targeted cancer therapy. chemotherapies. However, through our comprehensive Brentuximab vedotin, a CD30-directed antibody conjugate, literature research we did not find any study that reported the specifically targets malignant HL cells.
    [Show full text]
  • ABVD Other Names: LYABVD
    For the Patient: ABVD Other names: LYABVD A Doxorubicin (also known as ADRIAMYCIN®) B Bleomycin V Vinblastine D Dacarbazine (also known as DTIC) Uses: • ABVD is a drug treatment given for Hodgkin's disease with the expectation of killing cancer cells. • ABVD is offered to patients with Hodgkin’s Lymphoma Treatment Plan: • Your treatment plan consists of several (up to 6) chemotherapy cycles. Each cycle lasts 4 weeks (=28 days). For each cycle, you will have two treatments given 2 weeks apart (Day 1 and Day 15). Each treatment consists of four chemotherapy drugs and a medicine called hydrocortisone (a steroid) injected into the vein. Two weeks after the second treatment (i.e. Day 29), you will start the next cycle. • The IV treatment takes about 3-4 hours. However, on Day 1 of each cycle, plan to spend part of that day at your treatment centre if you have a doctor’s appointment and a blood test. • Drugs: • Four chemotherapy drugs (doxorubicin, bleomycin, vinblastine, dacarbazine), and hydrocortisone are given as an IV injection in your arm on Day 1 and Day 15 of each cycle. • You take anti-nausea pills to help prevent nausea and vomiting. The anti- nausea prescription is filled at your drugstore. • During the course of your treatment, your cancer doctor may decide that you need a drug called filgrastim (also known as G-CSF, granulocyte colony stimulation factor) to improve your white blood cell count. If it is needed, the filgrastim is given as an injection under the skin (subcutaneous, SC) daily for 3 to 5 days, starting a few days after the chemotherapy (your doctor will specify when to start this).
    [Show full text]
  • ABVD Versus Modified Stanford V Versus MOPPEBVCAD With
    ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C, Pavone V , Cavanna L, Santini G , Merli F , Liberati M ,Baldini L , Deliliers GL, Angelucci E, Bordonaro R , Federico M ;Intergruppo Italiano Linfomi . PURPOSE: In this multicenter, prospective, randomized clinical trial on advanced Hodgkin's lymphoma (HL), the efficacy and toxicity of two chemotherapy regimens, doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide, and prednisone (Stanford V) and mechlorethamine, vincristine, procarbazine, prednisone, epidoxirubicin, bleomycin, vinblastine, lomustine, doxorubicin, and vindesine (MOPPEBVCAD), were compared with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as standard therapy to select which regimen would best support a reduced radiotherapy program, which was limited to < or = two sites of either previous bulky or partially remitting disease (a modification of the original Stanford program). PATIENTS AND METHODS: Three hundred fifty-five patients with stage IIB, III, or IV HL were randomly assigned. Three hundred thirty-four patients were assessable for the study and received six cycles of ABVD (n = 122), three cycles of Stanford V (n = 107), or six cycles of MOPPEBVCAD (n = 106); radiotherapy was administered to 76, 71, and 50 patients in these three arms, respectively. RESULTS: The complete response rates for ABVD, Stanford V, and MOPPEBVCAD were 89%, 76% and 94%, respectively; 5-year failure-free survival (FFS) and progression-free survival rates were 78%, 54%, 81% and 85%, 73%, and 94%, respectively (P < .01 for comparison of Stanford V with the other two regimens).
    [Show full text]